{
  "trial_id": "NCT04570397",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "age",
      "label": "met",
      "evidence": "18 years old"
    },
    {
      "criterion": "sex",
      "label": "met",
      "evidence": "male"
    },
    {
      "criterion": "weight",
      "label": "met",
      "evidence": "40kg or above"
    },
    {
      "criterion": "thrombotic microangiopathy diagnosis",
      "label": "met",
      "evidence": "clinical diagnosis with D-dimer > 100% and/or serum creatinine >25%"
    },
    {
      "criterion": "SARS-CoV-2 infection",
      "label": "met",
      "evidence": "diagnosis within 90 days prior to enrollment"
    }
  ],
  "exclusion": [
    {
      "criterion": "survival expectation",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Neisseria Meningitides infection",
      "label": "not_met",
      "evidence": "unresolved"
    },
    {
      "criterion": "hypersensitivity to murine proteins or excipients of ravulizumab",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "notes": "The patient has a history of vaccination with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine, but this is not relevant to the trial. The genetic survey revealed ADAMTS13 >10%, which suggests that the patient's condition may be related to atypical hemolytic uremic syndrome.",
  "_meta": {
    "topic_id": "68",
    "trial_id": "NCT04570397",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}